Meet our community and take part in MI!
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
Jean-Paul BORG
AMU, IPC, CRCM
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
Vincent FERT
Veracyte
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Catherine FARNARIER
AP-HM
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
Frédéric VELY
AMU, AP-HM, CIML
Today, the Covid-19 pandemic serves as an eye-opener, once again demonstrating the strength of the Marseille Immunopôle collective
Nassima CHOUAKI BENMANSOUR
AP-HM
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the γ9δ2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Pierre d’EPENOUX
Imcheck Therapeutics
MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably
Emilie GARRIDO-PRADALIE
AP-HM
As such, we are involved in the Marseille immunology biotope
Michel MANCIS
Protisvalor
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
Jacques PFISTER
CCI Marseille Provence
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
Fabrice BARLESI
Université Paris-Saclay, Gustave Roussy, The Pioneer Project
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.
Florence SABATIER
AMU, AP-HM
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
Nicolas SCHLEINITZ
AP-HM, AMU
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.
Jean-Robert HARLÉ
AMU, AP-HM
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Bernard MALISSEN
CIPHE, CIML
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
Michel AURRAND-LIONS
AMU, IPC, CRCM
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
Pascale TOMASINI
AP-HM, AMU
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
Marcel BLOT-CHABAUD
VRCM
The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma
Bernard A. FOX
Providence Cancer Institute, Portland, Oregon | UbiVac
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Julien CARVELLI
AP-HM
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
Mondher MAHJOUBI
Innate Pharma
“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”
Stéphane PROVENT
Centre Hospitalier, Clinique Maymard, Bastia
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM
“Histopathology is critical to establish a diagnosis based on microscopic tissue examination, but is also of great importance to medical research protocols such as The PIONeeR Project.”
Laurence BAGUR MISTRE
AP-HM
Education is also one of the strategic components of the Marseille Immunopole project.
Françoise DIGNAT-GEORGE
AMU, AP-HM, C2VN
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
Francois ROMAGNÉ
AMU, MI-mAbs
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
Cathy LAPORTE
Marseille Immunopôle
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better
Vincent BARLOGIS
AP-HM
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
Alice CARRIER
AMU, IPC, CRCM
We have developed a library of human tumors xenografted on immunodepressed mice
Michel IOVANNA JUAN
AMU, IPC, CRCM
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
Éric VIVIER
AMU, AP-HM, CIML, INNATE PHARMA
The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.
Hervé BRAILLY
Innate Pharma
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
Bruno LACARELLE
AP-HM, AMU
The Pioneer Project draws on the collaborative environment of Marseille Immunopôle, which brings together clinicians, academics and industry players committed to the benefit of patients
Laurent GREILLIER
AP-HM, AMU
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Fabienne HERMITTE
Veracyte
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
Christian CHABANNON
AMU, IPC, AP-HM, Inserm
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Delphine BADINAND
APHM
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
Daniel OLIVE
AMU, IPC, CRCM
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
Norbert VEY
AMU, IPC
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
Émilie ROYERE
Eurobiomed
A therapeutic revolution is happening.
Bertrand NADEL
CIML, Institut Carnot CALYM, Cancéropole PACA
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
Jean-Paul BORG
AMU, IPC, CRCM
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
Vincent FERT
Veracyte
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Catherine FARNARIER
AP-HM
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
Frédéric VELY
AMU, AP-HM, CIML
Today, the Covid-19 pandemic serves as an eye-opener, once again demonstrating the strength of the Marseille Immunopôle collective
Nassima CHOUAKI BENMANSOUR
AP-HM
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the γ9δ2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Pierre d’EPENOUX
Imcheck Therapeutics
MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably
Emilie GARRIDO-PRADALIE
AP-HM
As such, we are involved in the Marseille immunology biotope
Michel MANCIS
Protisvalor
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
Jacques PFISTER
CCI Marseille Provence
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
Fabrice BARLESI
Université Paris-Saclay, Gustave Roussy, The Pioneer Project
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.
Florence SABATIER
AMU, AP-HM
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
Nicolas SCHLEINITZ
AP-HM, AMU
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.
Jean-Robert HARLÉ
AMU, AP-HM
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Bernard MALISSEN
CIPHE, CIML
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
Michel AURRAND-LIONS
AMU, IPC, CRCM
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
Pascale TOMASINI
AP-HM, AMU
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
Marcel BLOT-CHABAUD
VRCM
The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma
Bernard A. FOX
Providence Cancer Institute, Portland, Oregon | UbiVac
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Julien CARVELLI
AP-HM
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
Mondher MAHJOUBI
Innate Pharma
“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”
Stéphane PROVENT
Centre Hospitalier, Clinique Maymard, Bastia
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM
“Histopathology is critical to establish a diagnosis based on microscopic tissue examination, but is also of great importance to medical research protocols such as The PIONeeR Project.”
Laurence BAGUR MISTRE
AP-HM
Education is also one of the strategic components of the Marseille Immunopole project.
Françoise DIGNAT-GEORGE
AMU, AP-HM, C2VN
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
Francois ROMAGNÉ
AMU, MI-mAbs
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
Cathy LAPORTE
Marseille Immunopôle
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better
Vincent BARLOGIS
AP-HM
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
Alice CARRIER
AMU, IPC, CRCM
We have developed a library of human tumors xenografted on immunodepressed mice
Michel IOVANNA JUAN
AMU, IPC, CRCM
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
Éric VIVIER
AMU, AP-HM, CIML, INNATE PHARMA
The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.
Hervé BRAILLY
Innate Pharma
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
Bruno LACARELLE
AP-HM, AMU
The Pioneer Project draws on the collaborative environment of Marseille Immunopôle, which brings together clinicians, academics and industry players committed to the benefit of patients
Laurent GREILLIER
AP-HM, AMU
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Fabienne HERMITTE
Veracyte
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
Christian CHABANNON
AMU, IPC, AP-HM, Inserm
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Delphine BADINAND
APHM
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
Daniel OLIVE
AMU, IPC, CRCM
The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.
Norbert VEY
AMU, IPC
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
Émilie ROYERE
Eurobiomed
A therapeutic revolution is happening.
Bertrand NADEL
CIML, Institut Carnot CALYM, Cancéropole PACA